Economics of preoperative radiotherapy with total mesorectal excision: What can we learn from the Dutch experience?

Journal of Clinical Oncology

Volumn 22, Issue 2, 2004, Pages 217-219

  Simunovic, Marko ^a   Gafni, Amiram ^a   Levine, Mark ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANUS SPHINCTER; CANCER RECURRENCE; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; EDITORIAL; HEALTH CARE COST; HUMAN; LIFE EXPECTANCY; LYMPH NODE; MANAGEMENT; MESORECTAL EXCISION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RECTUM CANCER; RECTUM SURGERY; TREATMENT OUTCOME; ADJUVANT THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST BENEFIT ANALYSIS; ECONOMICS; MULTIMODALITY CANCER THERAPY; NOTE; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RECTUM TUMOR; SURVIVAL;

COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; HUMANS; LIFE EXPECTANCY; NEOADJUVANT THERAPY; QUALITY-ADJUSTED LIFE YEARS; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIALS; RECTAL NEOPLASMS; SURVIVAL ANALYSIS;

EID: 1342268529     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.11.918     Document Type: Editorial

References (17)

1. Swedish Rectal Cancer Trial: Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 336:980-987, 1997
2. Krook JE, Moertel CG, Gunderson LL, et al: Effective adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 324:709-715, 1991
3. NIH Consensus Conference: Adjuvant therapy for patients with colon and rectal cancer. JAMA 264:1444-1450, 1990
4. MacFarlane JK, Ryall R, Heald RJ: Mesorectal excision for rectal cancer. Lancet 341:457-460, 1993
5. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al: Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345:638-646, 2001
6. van den Brink M, van den Hout WB, Stiggelbout AM, et al: Cost-utility analysis of preoperative radiotherapy in patients with rectal cancer undergoing total mesorectal excision. J Clin Oncol 22: 10.1200/JCO.2004.04.198
7. Drummond MF, Richardson WS, O'Brien BJ, et al: Users' guides to the medical literature, XIII: How to use an article on economic analysis of clinical practice, A-Are the results of the study valid? Evidence-Based Medicine Working Group JAMA 277:1552-1557, 1997
8. O'Brien BJ, Heyland D, Richardson WS, et al: Users' guides to the medical literature, XIII: How to use an article on economic analysis of clinical practice, B-What are the results and will they help me in caring for my patients? Evidence-Based Medicine Working Group [published erratum appears in JAMA 278:1064, 1997]. JAMA 277:1802-1806, 1997
9. Simunovic M, Sexton R, Rempel E, et al: Optimal preoperative assessment and surgery for rectal cancer may greatly limit the need for radiotherapy. Br J Surg 90:999-1003, 2003
10. Martling A, Cedermark B, Johansson H, et al: The surgeon as a prognostic factor after the introduction of total mesorectal excision in the treatment of rectal cancer. Br J Surg 89:1008-1013, 2002
11. Nagtegaal ID, van de Velde CJH, van der Worp E, et al: Macroscopic evaluation of rectal cancer resection specimen: Clinical significance of the pathologist in quality control. J Clin Oncol 20:1729-1734, 2002
12. Dahlberg M, Stenborg A, Pahlman L, et al: Swedish Rectal Cancer Trial: Cost-effectiveness of preoperative radiotherapy in rectal cancer-Results from the Swedish Rectal Cancer Trial. Int J Radiat Oncol Biol Phys 54:654-660, 2002
13. Gold MR, Russel LB, Weinstein MC: Cost-Effectiveness in Health and Medicine. New York, NY, Oxford Univ Press, 1996
14. Weinstein MC, Stason WB: Foundation of cost effectiveness analysis for health and medical practice. N Engl J Med 296:716-721, 1977
15. Birch S, Gafni A: Cost effectiveness/utility analyses: Do current decision rules lead us to where we want to be? J Health Econ 11:279-296, 1992
16. Birch S, Gafni A: Changing the problem to fit the solution: Johannesson and Weinstein's (mis)application of economics to real world problems. J Health Econ 12:469-476, 1993
17. Sendi P, Gafni A, Birch S: Opportunity costs and uncertainty in the economic evaluation of health care interventions. Health Econ 11:23-31, 2002